On one hand, Type I IFN-β signalling through IRF-3 and canonical NF-κB signalling (RelA/NF-κB1) is known to enhance MHC-I expression, immune targeting and tumour clearance [9]. The gene discussed is NFKB1; the disease is neoplasm.